Effects of the α2/α3-subtype-selective GABAA receptor positive allosteric modulator KRM-II-81 on pain-depressed behavior in rats: comparison with ketorolac and diazepam.


Journal

Behavioural pharmacology
ISSN: 1473-5849
Titre abrégé: Behav Pharmacol
Pays: England
ID NLM: 9013016

Informations de publication

Date de publication:
08 2019
Historique:
pubmed: 15 1 2019
medline: 3 3 2020
entrez: 15 1 2019
Statut: ppublish

Résumé

This study examined effects of the α2/α3-subtype-selective GABAA receptor positive allosteric modulator KRM-II-81 in an assay of pain-related behavioral depression. Adult, male Sprague-Dawley rats responded for electrical brain stimulation in a frequency-rate intracranial self-stimulation (ICSS) procedure. Intraperitoneal injection of 1.8% lactic acid served as an acute noxious stimulus to depress ICSS. Effects of KRM-II-81 were evaluated in the absence and presence of the acid noxious stimulus. The NSAID ketorolac and the benzodiazepine diazepam were tested as comparators. Neither ketorolac nor KRM-II-81 altered ICSS in the absence of the acid noxious stimulus; however, diazepam produced facilitation consistent with its abuse liability. Ketorolac blocked acid-induced depression of ICSS, and effects of 1.0 mg/kg ketorolac lasted for at least 5 h. KRM-II-81 (1.0 mg/kg) produced significant antinociception after 30 min that dissipated by 60 min. Diazepam also attenuated acid-depressed ICSS, but only at doses that facilitated ICSS when administered alone. The lack of ketorolac or KRM-II-81 effects on ICSS in the absence of the acid noxious stimulus suggests low abuse liability for both compounds. The effectiveness of ketorolac to block acid-induced ICSS depression agrees with clinical analgesic efficacy of ketorolac. KRM-II-81 produced significant but less consistent and shorter-acting antinociception than ketorolac.

Identifiants

pubmed: 30640180
doi: 10.1097/FBP.0000000000000464
pmc: PMC6610697
mid: NIHMS1516668
doi:

Substances chimiques

Analgesics 0
KRM-II-81 0
Oxazoles 0
Receptors, GABA-A 0
Diazepam Q3JTX2Q7TU
Ketorolac YZI5105V0L

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

452-461

Subventions

Organisme : NINDS NIH HHS
ID : R01 NS076517
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH096463
Pays : United States
Organisme : NIDA NIH HHS
ID : T32 DA007027
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS070715
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL118561
Pays : United States

Références

Nature. 2005 Dec 15;438(7070):1017-21
pubmed: 16355225
J Cardiovasc Pharmacol. 2007 Nov;50(5):470-9
pubmed: 18030055
Exp Clin Psychopharmacol. 2015 Oct;23(5):395-404
pubmed: 26098473
Neuropsychopharmacology. 2014 Jan;39(2):477-87
pubmed: 24045508
Drug Alcohol Rev. 2011 May;30(3):300-5
pubmed: 21545561
Eur J Pharmacol. 1995 Mar 6;275(2):153-62
pubmed: 7796850
Neurosci Lett. 2008 Jun 6;437(3):170-4
pubmed: 18406524
Neuropsychopharmacology. 2013 May;38(6):1006-14
pubmed: 23303046
Methods Mol Biol. 2010;617:79-91
pubmed: 20336415
J Comp Neurol. 2012 Dec 1;520(17):3895-911
pubmed: 22522945
Neuropharmacology. 2009 Jan;56(1):141-8
pubmed: 18760291
Adv Pharmacol. 2006;54:1-27
pubmed: 17175808
J Med Chem. 2018 Mar 22;61(6):2422-2446
pubmed: 29481759
Pain. 2009 Feb;141(3):233-8
pubmed: 19091469
Neuropharmacology. 2011 Mar;60(4):626-32
pubmed: 21145329
Pharmacol Rev. 2014 Jul;66(3):869-917
pubmed: 24973197
Behav Pharmacol. 1998 Mar;9(2):81-92
pubmed: 10065928
J Pharmacol Exp Ther. 2006 Nov;319(2):507-14
pubmed: 16751251
Trends Pharmacol Sci. 2009 Sep;30(9):453-9
pubmed: 19729210
J Pharmacol Exp Ther. 2015 Feb;352(2):208-17
pubmed: 25406170
J Neurosci. 2002 May 1;22(9):3765-75
pubmed: 11978852
Pain. 2005 Jan;113(1-2):9-19
pubmed: 15621359
J Pharmacol Exp Ther. 2010 Jan;332(1):4-16
pubmed: 19789360
Br J Anaesth. 1987 Jan;59(1):61-77
pubmed: 2881564
Anesth Analg. 1997 Jul;85(1):37-43
pubmed: 9212119
J Pharmacol Exp Ther. 2012 Mar;340(3):501-9
pubmed: 22128346
Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):915-20
pubmed: 15644443
Psychopharmacology (Berl). 2017 Jul;234(14):2091-2101
pubmed: 28365836
Anesth Analg. 2004 Jun;98(6):1521-7, table of contents
pubmed: 15155300
J Pharmacol Exp Ther. 1979 Aug;210(2):301-10
pubmed: 458637
Best Pract Res Clin Gastroenterol. 2010 Apr;24(2):121-32
pubmed: 20227026
Pharmacol Biochem Behav. 2011 Mar;98(1):35-42
pubmed: 21147151
J Pharmacol Exp Ther. 2008 Dec;327(3):969-81
pubmed: 18791060
J Med Chem. 2016 Dec 8;59(23):10800-10806
pubmed: 27933953
Anesth Analg. 2010 Mar 1;110(3):780-9
pubmed: 20185657
J Int Med Res. 1990 Jul-Aug;18(4):298-304
pubmed: 2227077
J Neurosci Methods. 2016 Apr 1;263:115-22
pubmed: 26891874
J Pharmacol Exp Ther. 2012 Nov;343(2):389-400
pubmed: 22892341
Clin Pharm. 1990 Dec;9(12):921-35
pubmed: 2292174
Brain Res Bull. 2017 May;131:62-69
pubmed: 28267561
Lab Anim (NY). 2013 Aug;42(8):292-300
pubmed: 23877610
J Pharmacol Exp Ther. 1990 Dec;255(3):1246-55
pubmed: 2262904
Neuropharmacology. 2018 Jul 15;137:332-343
pubmed: 29778948
J Pain. 2013 Mar;14(3):246-59
pubmed: 23332494
Adv Pharmacol. 2015;72:37-51
pubmed: 25600366
J Neurosci. 1996 Jan;16(1):283-97
pubmed: 8613794
Anesth Analg. 2014 Apr;118(4):854-62
pubmed: 24651240
Pain. 2015 Jun;156(6):1153-60
pubmed: 25827812
JAMA. 2018 Jul 10;320(2):129-130
pubmed: 29896636
Pain. 2014 Aug;155(8):1659-66
pubmed: 24861580
Curr Top Med Chem. 2011;11(9):1176-202
pubmed: 21050172
Ann Intern Med. 2016 Jul 19;165(2):103-12
pubmed: 27136278
Ann Emerg Med. 2017 Aug;70(2):169-176.e1
pubmed: 28187918
Pain. 2009 Jul;144(1-2):170-7
pubmed: 19435650
Nat Commun. 2015 Apr 13;6:6803
pubmed: 25865415
Psychopharmacology (Berl). 1995 Mar;118(2):107-15; discussion 118, 120-1
pubmed: 7617794
Nature. 2008 Jan 17;451(7176):330-4
pubmed: 18202657
J Comp Neurol. 1992 Dec 8;326(2):193-216
pubmed: 1336019
Drugs. 1980 Mar;19(3):195-219
pubmed: 6102508
J Neurosci. 2002 Aug 1;22(15):6724-31
pubmed: 12151551
Anesthesiology. 2004 Jul;101(1):191-203
pubmed: 15220791
Science. 1965 Nov 19;150(3699):971-9
pubmed: 5320816
Nat Protoc. 2007;2(11):2987-95
pubmed: 18007634
N Engl J Med. 2017 Jul 27;377(4):391-394
pubmed: 28564549
ACS Chem Neurosci. 2017 Jun 21;8(6):1305-1312
pubmed: 28150939
Neuropharmacology. 2016 Oct;109:366-375
pubmed: 27392635
AANA J. 2014 Feb;82(1):53-64
pubmed: 24654353

Auteurs

Megan J Moerke (MJ)

Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia.

Guanguan Li (G)

Department of Chemistry and Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.

Lalit K Golani (LK)

Department of Chemistry and Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.

James Cook (J)

Department of Chemistry and Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.

S Stevens Negus (SS)

Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH